nach oben

Erschienen in:

01.03.2013 | Editorial

Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?

Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO)

verfasst von: F. Sedlmayer, M.L. Sautter-Bihl, W. Budach, J. Dunst, P. Feyer, R. Fietkau, W. Haase, W. Harms, C. Rödel, R. Souchon, F. Wenz, R. Sauer, Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Excerpt

Adjuvant radiotherapy following breast conserving surgery (BCS) is usually performed by homogenous irradiation of the whole breast (WBI), using single doses of 1.8–2 Gy up to total doses around 50 Gy, mostly followed by a boost to the tumor bed considered as the area of highest subclinical tumor cell contamination [19]. This tumor bed boost may be applied using external photon and/or electron beams up to cumulative tumor bed doses of 60–66 Gy in same fractional dose sizes as the preceding WBI. Alternatively, higher single fractions around 10 Gy are commonly used for either brachytherapy or intraoperative tumor bed boosts (IORT). …

Bantema-Joppe EJ, Schilstra C, deBock GH et al (2012) Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months’ follow-up. Int J Radiat Oncol Biol Phys 83:e471–477PubMedCrossRef

Bantema-Joppe EJ, van der Laan HP, de Bock GH et al (2011) Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. Radiother Oncol 100:215–220PubMedCrossRef

Bentzen SM, Yarnold JR (2010) Reports of unexpected late side effects of accelerated partial breast irradiation—radiobiological considerations. Int J Radiat Oncol Biol Phys 77:969–973PubMedCrossRef

Baack T, Wenz F (2012) Secondary cancers after radiotherapy may appear early and atypical. Strahlenther Onkol 188:91–92; author reply 92–93PubMedCrossRef

Chadha M, Vongtama D, Friedmann P et al (2012) Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer 12:57–62PubMedCrossRef

Coles C, Yarnold J (2006) IMPORT Trials Management Group. The IMPORT trials are launched. Clin Oncol (R Coll Radiol) 18:587–590

Collette S, Collette L, Budiharto T et al (2008) Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882“boost versus no boost“. Eur J Cancer 44:2587–2599PubMedCrossRef

Donovan EM, James H, Bonora M et al. (2012) Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer. Med Phys 39:5814–5824PubMedCrossRef

Fowler JF (1992) Brief summary of radiobiological principles in fractionated radiotherapy. Sem Radiat Oncol 2:16–21CrossRef

10.

Freedman GM, Anderson PR, Bleicher RJ et al (2012) Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer. Int J Radiat Oncol Biol Phys 84:888–893PubMedCrossRef

11.

Freedman GM, Anderson PR, Goldstein LJ, et al (2007) Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys 68:347–353PubMedCrossRef

12.

Goldsmith C, Haviland J, Tsang Y et al (2011) Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation? Radiother Oncol 100:236–240PubMedCrossRef

13.

Hurkmans CW, Dijckmans I, Reijnen M et al (2012) Adaptive radiation therapy for breast IMRT-simultaneously integrated boost: three-year clinical experience. Radiother Oncol 103:183–187PubMedCrossRef

14.

Hurkmans CW, Meijer GJ, van Vliet-Vroegindeweij C et al (2006) High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization. Int J Radiat Oncol Biol Phys 66:923–930PubMedCrossRef

15.

Jagsi R, Ben-David MA, Moran JM et al. (2010) Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys 76:71–78PubMedCrossRef

16.

Moody AM, Mayles WP, Bliss JM et al (1994) The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol 33:106–112PubMedCrossRef

17.

Mukesh M, Harris E, Jena R et al (2012) Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiother Oncol 104:1–10PubMedCrossRef

18.

Nestle-Krämling C, Bölke E, Budach W et al (2011) [Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]. Strahlenther Onkol 187:656–664PubMedCrossRef

19.

Sautter-Bihl ML, Budach W, Dunst J et al (2007) DEGRO Practical Guidelines for Radiotherapy of Breast Cancer I. Breast-Conserving Therapy. Strahlenther Onkol 183:661–666PubMedCrossRef

20.

Van Parijs H, Miedema G, Vinh-Hung V et al (2012) Short course radiotherapy with simultaneous integrated boost for stage I–II breast cancer, early toxicities of a randomized clinical trial. Radiation Oncology 7:80CrossRef

21.

Vrieling C, Collette L, Fourquet A et al (2000) The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC“boost versus no boost“ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 55:219–232PubMedCrossRef

22.

Whelan T, Pignol JP, Levine MN et al (2010) Long-term results of hypofractionated radiation therapy of breast cancer. NEJM 362:513–520PubMedCrossRef

23.

Yang Z, Chen J, Xie J, et al.(2012) Simultaneous Integrated Boost in Breast Conserving Radiotherapy: Is Replanning Necessary Following Tumor Bed Change? Technol Cancer Res Treat Oct 19 (Epub ahead of print)

24.

Yarnold J, Ashton A, Bliss J et al (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: Long – term results of a randomised trial. Radiother Oncol 75:9–17PubMedCrossRef

Titel: Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?
Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO)
verfasst von: F. Sedlmayer
M.L. Sautter-Bihl
W. Budach
J. Dunst
P. Feyer
R. Fietkau
W. Haase
W. Harms
C. Rödel
R. Souchon
F. Wenz
R. Sauer
Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO)
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0300-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Is the simultaneously integrated boost (SIB) technique for early breast cancer ready to be adopted for routine adjuvant radiotherapy?

Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO)

Excerpt

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients

Dysphagia after definitive radiotherapy for head and neck cancer

Mitteilungen der Fachgesellschaften

Erratum to: Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al.

Cyclin D1, EGFR, and Akt/mTOR pathway

In vitro hypoxic cytotoxicity and hypoxic radiosensitization

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie